RayKnowChina Research Map
Shortlist0

Guangzhou

Guangdong Second Provincial General Hospital

广东省第二人民医院

Listed for 11 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Guangdong Second Provincial General Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Hepatocellular carcinoma肝细胞癌16 papers led
  3. Osteosarcoma骨肉瘤2 papers led
  4. Neuroblastoma神经母细胞瘤1 paper led
  5. Multiple myeloma多发性骨髓瘤3 papers led1 open trial led
  6. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  7. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
  8. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  9. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  10. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  11. Behçet disease白塞病0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryRadiology / nuclear medicine
Papers it led3
  1. Voice Changes of Patients With Nasopharyngeal Carcinoma in Eleven Years After Radiotherapy: A Cross-Sectional Study.2026Journal of voice : official journal of the Voice Foundation
  2. Electrophysiological Changes on Laryngeal Motor Neuropathways Cause Voice Disorders for Postradiotherapy Patients with Nasopharyngeal Carcinoma.2026Journal of voice : official journal of the Voice Foundation
  3. Glutathione-Driven Disassembly of Planar Organic Phototherapeutic Agents to Enhance Photodynamic-Photothermal Therapy Performance for Nasopharyngeal Carcinoma.2025Small (Weinheim an der Bergstrasse, Germany)
More papers found outside PubMed (not counted)10
  1. 1376P A comprehensive overview of immune-related adverse events induced by immune checkpoint inhibitors in nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.2025Journal of Clinical Oncologyarticle
  3. 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2024Annals of Oncologyarticle
  4. 455P A real-world study: Induction chemoimmunotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with stage IVa2024Annals of Oncologyarticle
  5. Microplastics Antagonize the Therapeutic Effect of Curcumin on Nasopharyngeal Carcinoma Through Inhibiting the Apoptosis Pathway2024SSRN Electronic Journalpreprint
  6. SICNet: Learning selective inter-slice context via Mask-Guided Self-knowledge distillation for NPC segmentation2024Journal of Visual Communication and Image Representationarticle
  7. Enhanced Multi-Task Nasopharyngeal Carcinoma Recurrence Prediction by Knowledge Distillation with Loss-Balanced Weighting Strategy2023International Conference on Intelligent Computing and Human-Computer Interaction (ICHCI)conference-paper
  8. Risk Factors Analysis of Post Anesthesia Induction Hypotension in Patients with Recurrent Nasopharyngeal Carcinoma2023Journal of medicine and health science.article
  9. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figsharereview
  10. Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography2022Rehabilitation Medicinearticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 1120222023: 3320232024: 5520242025: 112025

14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC.2025Molecular cancerFree full text
  2. DEAD-box helicase 1 inhibited CD8+ T cell antitumor activity by inducing PD-L1 expression in hepatocellular carcinoma.2024Cancer science
  3. Phase separation of RNF214 promotes the progression of hepatocellular carcinoma.2024Cell death & diseaseFree full text
  4. Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.2024Journal of medicinal chemistry
  5. The Prognostic Value of Alpha-Fetoprotein Ratio in Patients With Resectable Alpha-Fetoprotein-Negative Hepatocellular Carcinoma.2024The American surgeon
  6. Low Expression of FAM96B is Associated with Poor Prognosis in Hepatocellular Carcinoma.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  7. Dual-targeting nanotheranostics for MRI-guided enhanced chemodynamic therapy of hepatoma via regulating the tumor microenvironment.2023Dalton transactions (Cambridge, England : 2003)
  8. Integrative analysis of disulfidptosis and immune microenvironment in hepatocellular carcinoma: a putative model and immunotherapeutic strategies.2023Frontiers in immunologyFree full text
  9. Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma.2023International journal of biological sciencesFree full text
  10. Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy.2022Disease markersFree full text
  11. Role of ATF3 as a prognostic biomarker and correlation of ATF3 expression with macrophage infiltration in hepatocellular carcinoma.2021BMC medical genomicsFree full text
  12. SSRP1 Is a Prognostic Biomarker Correlated with CD8+ T Cell Infiltration in Hepatocellular Carcinoma (HCC).2021BioMed research internationalFree full text
  13. T-bet transduction enhances anti-tumor efficacy of IFN-producing dendritic cell (IKDC) against hepatocellular carcinoma via apoptosis induction.2021Biochemical and biophysical research communications
  14. MiR-3188 regulates the proliferation and apoptosis of hepatocellular carcinoma cells by targeting CXCL14.2021Biomarkers in medicine
  15. Distribution of serum Thrombospondin-2, a novel tumor marker, in general population and cancer patients in China.2021Clinica chimica acta; international journal of clinical chemistry
  16. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375.2021IUBMB life

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-03
    Registry
    NCT06298266

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Second Provincial General HospitalGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRelapse & resistanceDrug combinationsCAR-T & cell therapy
Papers it led3
  1. Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECSO.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. Receptor T-Cell Chimeric Antigen Approach Used for the Prediction Model Treatment for Relapsed/Refractory Multiple Myeloma.2024Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  3. Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma.2023Free radical biology & medicine
All its trials on ClinicalTrials.gov, any status1
  1. To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06298266Lead sponsorEarly phase 1Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenEBV & infection triggersLymphoma & cancer-related HLH
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

7 hospitals in Guangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

7 hospitals in Guangzhou for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广东省第二人民医院

Guangdong Second Provincial General Hospital

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Guangdong Second Provincial Hospital; GGH; Guangdong Provincial People's Hospital; Second People's Hospital of Guangdong Province

Suggest a correctionDownload the data